全球荷爾蒙避孕藥及不孕症藥物市場(2011∼2018年):節制生育與生殖健康未來治療法

全球荷爾蒙避孕藥及不孕症藥物市場(2011∼2018年):節制生育與生殖健康未來治療法 是由出版商Urch Publishing, Ltd.在2011年05月所出版的。 這份英文市場調查報告書包含67 Pages 價格從美金2815起跳。

簡介

目前荷爾蒙避孕藥及不孕症藥物市場規模為95億美元,但今後將以7%年率增加，預測到2014年將到達100億美元。

本報告匯整目前的產品市場、研究開發主題、同領域的企業活動等資料，連同到2018年為止的銷售額預測及研究開發系統，為您概述為以下內容。

摘要整理

第1章 避孕和不孕:市場概要

• 市場資料
  • 生殖健康市場概要
  • 市場分析

第2章 荷爾蒙避孕藥產品市場

• 避孕藥
• 雌激素加黃體素併用避孕藥
• 只含黃體素的避孕藥
• 荷爾蒙避孕藥產品市場
  • Bayer healthcare Phramaceuticals
    • 主要產品和投資組合
    • 開發平台趨勢
    • 銷售額及產品市場預測
  • Johnson & Johnson
    • 主要產品和投資組合
    • 銷售額及產品市場預測
  • Merck & Co
    • 主要產品和投資組合
    • 銷售額及產品市場預測
  • Pfizer
    • 主要產品和投資組合
    • 銷售額及產品市場預測
  • Teva Pharmaceutical Industries
    • 主要產品和投資組合
    • 開發平台
    • 銷售額及產品市場預測
  • 學名藥醫藥品:Watson Pharmaceuticals
• 未來的考察和市場預測

第3章 不孕症藥物產品市場

• 概要
• 治療不孕病的藥物療法
• 不孕症藥物產品市場
  • AstraZeneca
    • 主要產品評論
    • 銷售額及產品市場預測
  • Ferring
    • 主要產品評論
    • 銷售額及產品市場預測
  • Merck & Co
    • 主要產品評論
    • 銷售額及產品市場預測
  • Merck Serono
    • 主要產品評論
    • 銷售額及產品市場預測
• 市場預測

第4章 生殖健康的研究開發

• 女性的口服避孕藥
  • 透過皮膚及粘膜的藥品
  • 植入式或注射式避孕藥
• 男性用避孕藥
• 避孕:研究開發概要
• 研究開發中的不孕症藥物
  • 女性用
  • 男性用
• 不孕症:研究開發概要

參考資訊

圖表

目錄

Abstract

Summary

The current market for hormonal contraceptives and infertility drugs is estimated at US$9.4bn, and is forecast to increase by 7% in annual revenues to US$10bn by 2014.

In this report, The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health (2nd Edition) the reader will be introduced to an analysis of current product markets, research and development themes, and company activities within the field.

The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Key findings of the report include

• The worldwide market for hormonal contraceptives is estimated at US$6.9bn in 2011, but is expected to decrease approximately 19.5% in annual revenues to US$5.5bn by 2018.
• Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.
• Currently, there are over 40 pipeline candidates for female and male contraception.
• The current worldwide market for infertility drugs is US$2.5bn; however the infertility therapy sector is underserved with drugs that are mainly focused on female infertility that induce ovulation for assisted conception programs.
• Market leaders in the infertility sector include Merck Serono, Merck & Co., and Ferring with estimated revenues for their infertility products in 2011 at US$955m, US$625m and US$550m, respectively.
• Drivers of growth will be through innovation to: reduce side effects associated with pituitary-gonadal drugs; enhance qualitative and quantitative aspects of ovulation and spermatogenesis; and improve overall fertilization and pregnancy-birth rates.
• The male and female infertility R&D area is poorly served with only 15 pipeline candidates identified as potential clinical candidates.

Questions answered by this report include:

• Which contraceptives and infertility drugs are the current and potential future market leaders
• What impact new drug approvals will have on the reproductive medicine drug market
• Which premarket drugs are identified as high-value products
• Which companies are developing hormonal contraceptives and infertility drugs
• Sales predictions to 2018 for leading contraceptives and infertility drugs
• How will newcomers affect the product positioning of market leaders
• What are niche market opportunities in reproductive medicine
• What the future outlook holds for hormonal contraceptives and infertility pharmacotherapies
• How companies are expanding the global reproductive medicine market through sophisticated reformulations and secondary indications for endocrinological and gynaecological disorders
• Which molecules and compounds are main R&D clusters in reproductive medicine

Research Methodology

The contents of this URCH Publishing report are derived from in-depth research-based surveys of the industry and proprietary analytical assessment tools. Source material also comprises the following:

• Company information
• Scientific periodicals
• Personal communication
• Product information
• Trade press articles
• Market analyst data
• News releases
• Public information datasets
• Internet-based research
• Conference proceedings
• Library research
• Medical/pharma associations

Table of Contents

Executive Summary

• Report Highlights
• Objectives of the Report

1. Contraception and Infertility: Market Snapshot

• Market data synopsis - contraception and infertility
• 1.1 Reproductive Health Market Overview
• 1.2 Market Analysis for Contraception and Infertility
  • 1.2.1 Contraception
  • 1.2.2 Infertility

2. Product Market for Hormonal Contraception

• 2.1 Contraceptive Formulations
• 2.2 Combined Estrogen-Progestogen Contraceptives
• 2.3 Progestogen-Only Contraceptives
• 2.4 Product Market for Hormonal Contraceptives
  • 2.4.1 Bayer Healthcare Pharmaceuticals
    • 2.4.1.1 Key Product and Portfolio Review
    • 2.4.1.2 Pipeline Focus
    • Contraceptive Patch
    • Intrauterine device
    • 2.4.1.3 Sales Estimates and Product Market Outlook
  • 2.4.2 Johnson & Johnson
    • 2.4.2.1 Key Product and Portfolio Review
    • 2.4.2.2 Sales Forecasts and Product Market Outlook
  • 2.4.3 Merck & Co
    • 2.4.3.1 Key Product and Portfolio Review
    • 2.4.3.2 Sales Estimates and Product Market Outlook
  • 2.4.4 Pfizer
    • 2.4.4.1 Key Product and Portfolio Review
    • 2.4.4.2 Sales Estimates and Product Market Outlook
  • 2.4.5 Teva Pharmaceutical Industries
    • 2.4.5.1 Key Product and Portfolio Review
    • 2.4.5.2 Pipeline Focus
    • 2.4.5.3 Sales Estimates and Product Market Outlook
    • Generics Focus - Watson Pharmaceuticals
• 2.5 Future Considerations and Outlook for the Contraceptive Product Market

3. Product Market for Infertility Drugs

• 3.1 Overview for Infertility Drugs
• 3.2 Pharmacotherapies for Infertility
• Mechanism of Action of Infertility Pharmacotherapeutics
• 3.3 Product Market for Infertility Drugs
  • 3.3.1 AstraZeneca
    • 3.3.1.1. Key Product Review
    • 3.3.1.2 Sales Estimates and Product Market Outlook
  • 3.3.2 Ferring
    • 3.3.2.1 Key Product and Portfolio Review
    • 3.3.2.2. Sales Estimates and Product Market Outlook
  • 3.3.3 Merck & Co
    • 3.3.3.1 Key Product and Portfolio Review
  • 3.3.4 Merck Serono
    • 3.3.4.1 Key Product and Portfolio Review
    • 3.3.4.2 Sales Estimates and Product Market Outlook
• 3.4 Market Outlook for Infertility Pharmacotherapeutics

4. Research and Development in Reproductive Health

• 4.1 Female Oral Contraception
  • 4.1.1 Transdermal/Transmucosal Contraceptives
  • 4.1.2 Implantable/Injectable Contraceptives
• 4.2 Male Contraception
• 4.3 Contraception - Research and Development Overview
• 4.4 Infertility Drugs in Research and Development
  • 4.4.1 Female Infertility
  • 4.4.2 Male Infertility
    • 6.3.2.1 Infertility - Research and Development Overview

Reference Sources

List of Tables

Research Methodology

• Table 1.1 Estimated Global Sales (US$m) & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018
• Table 2.1 Selection of Hormonal Contraceptives Segmented by Formulation and Delivery Route, 2011
• Table 2.2 Bayer' s Hormonal Contraceptive Product Portfolio, 2011
• Table 2.3 Bayer`s Pipeline Contraceptive Candidates, 2011
• Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Bayer' s Leading Hormonal Contraceptive Products, 2011-2018
• Table 2.5 Johnson & Johnson`s Hormonal Contraceptive Product Portfolio, 2011
• Table 2.6 Estimated Sales (US$m) and Annual Growth (%) of Johnson & Johnson`s Leading Hormonal Contraceptive Products, 2011-2018
• Table 2.7 Merck & Co' s Hormonal Contraceptive Product Portfolio, 2011
• Table 2.8 Estimated Sales (US$m) and Annual Growth (%) of Merck & Co' s Leading Hormonal Contraceptive Products, 2011-2018
• Table 2.9 Pfizer`s Hormonal Contraceptive Product Portfolio, 2011
• Table 2.10 Estimated Sales (US$m) and Annual Growth (%) of Pfizer`s Leading Hormonal Contraceptive Products, 2011-2018
• Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011
• Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011 (continued)
• Table 2.12 Estimated Sales (US$m) and Annual Growth (%) of Teva`s Leading Hormonal
• Table 3.1 Pharmacotherapies for Infertility, 2011
• Table 3.2 Ferring`s Infertility Product Portfolio, 2011
• Table 3.3 Estimated Global Sales (US$m) and Annual Growth (%) of Ferring`s Infertility Products, 2011-2018
• Table 3.4 Merck & Co.`s Hormonal Infertility Product Portfolio, 2011
• Table 3.5 Estimated Global Sales (US$m) and Annual Growth (%) of Merck & Co.' s Hormonal Infertility Products, 2011-2018
• Table 3.6 Merck Serono`s Hormonal Infertility Product Portfolio, 2011
• Table 3.7 Estimated Global Sales (US$m) and Annual Growth (%) of Merck Serono`s Hormonal Infertility Products, 2011-2018
• Table 4.1 Female Oral Contraceptives in Development, 2011
• Table 4.1 Female Oral Contraceptives in Development, 2011 (continued)
• Table 4.2 Transdermal/Transmucosal Female Contraceptives in Development, 2011
• Table 4.3 Implantable/Injectable Female Contraceptives in Development, 2011
• Table 4.4 Male Contraceptives in Development, 2011
• Table 4.5 Drugs in Development for Female Infertility, 2011
• Table 4.6 Drugs in Development for Male Infertility, 2011

List of Figures

• Figure 1.1 Estimated Sales (US$m) and Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018
• Figure 1.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2011 & 2018
• Figure 2.1 Global Revenue Trends for Bayer' s Leading Hormonal Contraceptive Products, 2005-2010
• Figure 2.2 Global Revenue Trends for Johnson & Johnson' s Leading Hormonal Contraceptive Products, 2005-2010
• Figure 2.3 Global Revenue Trends for Merck & Co' s Leading Hormonal Contraceptive Products, 2005-2010
• Figure 2.4 Global Product Sales for Pfizer' s Hormonal Contraceptive Franchise, 2005-2010
• Figure 2.5 Global Sales Trends of Teva' s Leading Hormonal Contraceptive Products, 2005-2010
• Figure 2.6 Leading Hormonal Contraceptive Products by Sales Revenue (US$m), 2011 (estimated)
• Figure 3.1 Global Sales Trends of Merck & Co.' s Leading Hormonal Infertility Products, 2005-2010
• Figure 3.2 Global Sales Trends of Merck Serono' s Leading Hormonal Infertility Products,
• Figure 3.3 Leading Hormonal Infertility Products by Sales Revenue (US$m), 2011 (estimated)

相關商品

藥物開發相關市場調查報告書

分析工具：癌症治療的蛋白激脢抗化劑
Analytical Tool - Protein Kinase Inhibitors in Oncology
價格 : US $ 6674
出版日期 : 2012年05月

乳癌，肺癌，Protein Kinase抗化劑:藥物開發策略分析
Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

白血病，肺癌，Protein Kinase抗化劑:藥物開發策略分析
Triple Analysis: Leukemia, Lung Cancer and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

Urch Publishing, Ltd.發行的製藥相關市場調查報告書

醫療相關經營者的合作·收購與合併契約年鑑:2012年

Partnering and M&A Yearbook

價格 : US $ 2995

出版日期 : 2012年01月

歐洲的孤兒藥物市場

Orphan Drug Markets in Europe

價格 : US $ 2900

出版日期 : 2011年11月

南美的醫療和醫藥品:市場與相關法規指南

Healthcare & Pharmaceuticals in Latin America A guide to the markets and regulations

價格 : US $ 2345

出版日期 : 2011年09月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!